Platelet aggregation to form a haemostatic plug, or thrombus, plays a key role in preventing bleeding from a wound. Recent studies have provided new insights into how platelet receptors are deployed during the interactions with the vascular subendothelial matrix that lead to haemostatic plug formation.
retraction', involving myosin and actin filaments within platelets that are linked via the integrin α IIb β 3 to extracellular fibrin, draws the edges of a wound together, reducing bleeding and supporting the healing process. Platelet remnants are removed later by phagocytes as endothelial cells spread back to cover the injury site.
Thrombosis is the pathological version of haemostasis, and a factor in its development may be a disequilibrium between the positive and negative feedback mechanisms that control the growth of a thrombus and limit its size to that adequate to deal with a bleeding injury. In thrombosis, unrestrained growth of a thrombus may lead to myocardial infarction by blockage of a critical cardiac vessel, or stroke as a result of a blockage of more remote vessels by pieces -known as emboli -broken off an unstable thrombus. The inhibition of platelet receptors or feedback loops has been shown to reduce the incidence of major cardiovascular disease, and there is great interest in developing improved strategies for its prevention. For this, a better understanding of the basic mechanisms involved in primary haemostasis is seen as absolutely essential.
Over the past 25 years, the structures and roles of the major platelet receptors involved in adhesion and aggregation have been unravelled. Genetic disorders where these receptors are absent or defective have certainly facilitated elucidation of their roles. Thus, GPIb is the platelet receptor for von Willebrand factor, which is involved in platelet adhesion at several stages; integrin α IIb β 3 is a receptor for several adhesive proteins that contain the sequence arginine-glycine-aspartate (RGD), but mainly fibrinogen; and several platelet glycoproteins, in particular the integrin α 2 β 1 and GPVI, are collagen receptors. In addition, a large number of receptors involved in positive or negative feedback control of platelet aggregation have been identified, including those for ADP, prostaglandins, thromboxanes, serotonin, platelet activating factor (PAF) and thrombin.
Attempts to elucidate in vivo haemostatic processes have been facilitated by the ability to simulate relevant in vivo conditions in vitro. This has involved the development of subendothelial-like matrices exposed to blood flow in perfusion chambers under conditions of shear similar to those encountered in various vessels [1, 2] . It is well established that shear varies enormously, depending on vessel cross-section, being lowest in the aorta and highest in the capillaries and arterioles. von Willebrand factor is critical for haemostasis at high shear rates and is dispensable at low shear rates; collagen receptors are important at all shear rates. The main components of the subendothelium involved in platelet adhesion and activation are the various types of collagen, as well as von Willebrand factor bound via its A3 domain to specific sites on collagens. How these various receptors interact with the matrix to produce regulated platelet adhesion and activation is the subject of much on-going research. This is well illustrated by the work of Savage et al. [3] , who have recently used these techniques together with confocal videomicroscopy to examine how platelets bind and are displaced on a collagen-coated surface subjected to various shear rates. The number of platelets that adhere to the surface and the size of the thrombi that they form, as well as the movement of individual platelets, can be quantified using this approach. Various antibodies were used to inhibit specific receptors and thereby test their role in the various stages of adhesion, activation and aggregation. As in earlier studies, inhibition of integrin α IIb β 3 allowed single platelet adhesion, but prevented thrombus growth at all shear rates by blocking platelet-platelet aggregation via fibrinogen. Inhibition of von Willebrand factor binding to collagen, or of von Willebrand factor binding to its platelet receptor GPIb, prevented platelet adhesion completely at a shear rate of 1500 sec -1 , partly at 500 sec -1 and not at all at 100 sec -1 . Inhibition of the integrin α 2 β 1 partly blocked adhesion as well as reducing aggregate size.
The major advantage of real-time confocal videomicroscopy is that the movements of single platelets can be followed and the average velocity of platelets interacting with a surface thereby determined. It has long been thought that the main function of the interaction between GPIb and von Willebrand factor is to initiate binding of platelets under high shear conditions, but it was earlier assumed that this is more or less an all-or-nothing effect, with a platelet either being stopped by the interaction or having a grazing encounter. But actually platelets are slowed by a series of multiple weak interactions, involving making and breaking single attachments between different GPIb receptors and von Willebrand factor molecules on the surface so that, at any given time, there are always some interactions holding the platelet in contact with the surface but it can nevertheless move across the surface. What brings this process to an end? One possibility is that, if the platelet is near the edge of a vascular lesion, it can move off the subendothelium onto endothelial cells, become detached and return to the circulation.
Recent studies with transfected cells making the GPIb complex have shown that these too roll on a vonWillebrand-factor-coated surface, though no firm adhesion was detected [4] . In the perfusion chamber system used, platelets move a certain distance and then adhere firmly. This definitive adhesion was prevented if integrins α 2 β 1 and α IIb β 3 were both inhibited, and most of the platelets were then displaced further. Firm adhesion was also prevented by inhibition of integrin α 2 β 1 in the presence of prostaglandin E 1 to block activation of α IIb β 3 . The binding via α IIb β 3 might be to the RGD sequence on von Willebrand factor bound to collagen [2, 5] , or it might be to other RGD-containing adhesive proteins, such as fibrinogen, vitronectin or fibronectin which are released from activated platelets. Similar results were obtained when subendothelial matrix was used instead of collagen type I.
Does integrin α 2 β 1 need to be activated for it to bind to collagen? Integrin α IIb β 3 does need to be activated to bind to the RGD sequence in fibrinogen and other proteins. The situation with regard to α 2 β 1 and collagen is much less clear. It was assumed that α 2 β 1 is constitutively active, simply because platelets aggregate in response to collagen and α 2 β 1 was the first, and for a long time the only, characterised platelet collagen receptor. But the characterisation of other collagen receptors, in particular GPVI, has cast doubt on this earlier assumption and recent studies comparing platelet binding to insoluble and 'soluble' collagen have provided the first real evidence that integrin activation does have an important role in platelet adhesion and stimulation [6] .
Integrins α IIb β 3 and α 2 β 1 are probably both activated as a result of platelet binding to the subendothelium via the interaction between von Willebrand factor and GPIb. As this latter interaction requires high shear stress, how does one explain platelet binding to the subendothelium and activation under low shear conditions? Binding to collagen is probably involved -platelets are aggregated by collagen, and this is inhibited by antibodies to a number of platelet collagen receptors as well as to α 2 β 1 . So there are probably mechanisms for activating α 2 β 1 during platelet interactions with collagen. GPVI is a prime candidate for being such a collagen receptor, and is also important for activation of α IIb β 3 under such conditions [7] . GPVIspecific agonists, such as collagen-related peptides, are capable of activating α IIb β 3 .
Platelets lacking GPVI can nevertheless still be activated, albeit weakly, by collagen; they do not aggregate but do show increased fibrinogen binding, indicating that there is some residual activation of α IIb β 3 [8] . This indicates that, while GPVI has an important role in activation of both integrins, other collagen receptors, including probably α 2 β 1 [9] , permit some α IIb β 3 activation in its absence. In order to test the activation state of α 2 β 1 convincingly, it will be necessary to develop specific, defined reagents for use as probes, in the same way that fibrinogen or specific monoclonal antibodies are used to probe for α IIb β 3 activation. The 'soluble' collagen described above may be adequate for this role, but will need to be characterised better.
The recent studies have revealed platelet adhesion and activation to be a stepwise process (Figure 2 ) with strong parallels to leukocyte migration at sites of inflammation. In both cases, weak 'rolling' interactions -mediated by GPIb and von Willebrand factor in the case of platelet adhesion, and selectins and their complex carbohydrate ligands in the case of leukocytes -are followed by firm adhesion mediated by integrins. Simultaneously, the adhesion process is enhanced via release of granule contents and cytoskeletal activation. (c) The activated platelet continues to spread on the subendothelium and more receptors are engaged.
Other platelets can bind to the surface-bound platelet via activated α IIb β 3 receptors and plasma or released platelet fibrinogen, and these become activated in their turn by granule contents and clustering of receptors.
